12-Jun-2026 19:06:10
IPCA LABS SIGNS GLOBAL BIOLOGICS TECHNOLOGY LICENSING DEAL
• 🌍 Ipca Laboratories entered a worldwide licensing agreement with Bhami Research Laboratory (BRL) • 🧬 Deal gives Ipca access to BRL’s high-concentration subcutaneous biologics delivery platform for multiple monoclonal antibody products • 🎯 Focus on developing biologics for oncology and inflammatory diseases • 🔬 BRL will handle Proof-of-Concept and formulation development, while Ipca will lead further R&D, clinical trials, manufacturing and commercialization • 💰 BRL to receive milestone payments for technology transfer and royalties on net sales after commercialization • 🇺🇸🇪🇺 Initiative targets major global markets including the US, UK, EU, Japan and South Korea 🟢 Impact: Positive — Strengthens Ipca’s biologics pipeline, expands presence in high-value specialty therapies and enhances long-term global growth opportunities.
T & I GLOBAL LTD.